Entero Therapeutics 的空头股数暴跌 55.3%，季度亏损每股 3.37 美元。 Entero Therapeutics sees short interest plunge 55.3% amid quarterly loss of $3.37 per share.

Entero Therapeutics（纳斯达克股票代码：ENTO）的空头股数在 11 月下降了 55.3%，从 152,900 股降至 68,300 股。 Entero Therapeutics (NASDAQ: ENTO) saw short interest drop by 55.3% in November, from 152,900 to 68,300 shares. 该公司报告每季度每股损失3.37美元,分析师预测当年的EPS为-1.13 EPS。 The company reported a quarterly loss of $3.37 per share, with analysts predicting a -1.13 EPS for the year. Entero治疗法的重点是发展胃肠道疾病的口服疗法,包括大肠杆菌病和胃炎的治疗。 Entero Therapeutics focuses on developing oral therapies for gastrointestinal diseases, including treatments for celiac disease and gastroparesis.